System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jose C Nicolau is an expert in Cardiology at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (Brazil). As of October 2026, ScienceLeadR ranks Jose C Nicolau in the top 1% of experts worldwide for Myocardial Ischemia, Coronary Disease and Arteriosclerosis. Jose C Nicolau has authored 538 publications, the most recent in 2026, and is an investigator in 66 clinical trials, 1 of them ongoing. SLR score: 2,304 (community average: 125). How the SLR is computed.

LeadR Profile

Jose C Nicolau Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Brazil
2 304 ScienceLeadR Reputation 2304

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Biochemistry - Endocrinology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Universidade de São Paulo

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 538

Citations

Citations: 70 993 1st author: 84 Last author: 108 Unique author: 6

Main journals

Arq Bras Cardiol 81
J Am Coll Cardiol 58
Circulation 48
N Engl J Med 35
Eur Heart J 33

Best Journals

N Engl J Med 34
Circulation 18
Eur Heart J 7

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide		JAMA Cardiol20260
Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.
PMID 42670293 — diabetes mellitus, mortality, ischemic stroke, stroke, myocardial infarction, lipoproteins, cardiovascular system, lipoproteins, hdl, cholesterol, atherosclerosis, lipoproteins, ldl, blood circulation, ischemia, apolipoproteins		Circulation Top journal20262
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
PMID 42670965 — safety, hemorrhage, ischemic stroke, stroke, myocardial infarction, acute coronary syndrome, therapeutics		N Engl J Med Top journal20261
Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.
PMID 42663360 — stroke, myocardial infarction, incidence, lipoproteins, cardiology, cholesterol, atherosclerosis, lipoproteins, ldl, ischemia		J Am Coll Cardiol20261
Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial.
PMID 42663056 — myocardial infarction, cardiology		Eur Heart J Top journal20260

Clinical Studies 66

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 2 Study Director: 1

By phase:

Phase 3 37
N/A 15
Phase 4 6
Phase 2 4
Phase 2/Phase 3 4

By status:

Completed 58
Terminated 6
Recruiting 1
Unknown 1

By type:

Interventional 61
Observational 5

By Monocentric/Multicentric:

monocentric 25
multicentric2to4 1
multicentric5to9 0
multicentricup10 40

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
NCT06286878 — diabetes mellitus, myocardial infarction, ventricular dysfunction, pharmaceutical preparations, acute coronary syndrome, biomarkers, glycemic control, diabetes mellitus, type 2		Phase 2/Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS